C-type lectin domain family 4 member EGenealiases: CLECSF9 · MINCLE
Q-omics provides the consensus-scored CLEC4E profile across patient tissues and cancer cell-line models. CLEC4E expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CLEC4E is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CLEC4E RNA expression shows 20,025 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where CLEC4E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC4E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC4E survival associations across molecular data types. CLEC4E RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC4E RNA expression–survival associations across cancer types. High CLEC4E expression shows unfavorable associations in THYM, but favorable associations in SKCM, HNSC, LUAD, THCA and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CLEC4E RNA expression.
This table summarizes CLEC4E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CLEC4E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC4E shows lower tumor expression in LUAD, LUSC, KICH and THCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher CLEC4E RNA expression in tumor versus normal tissue (log2 FC = +0.681, t-test p < 0.001).
This table shows molecular features associated with CLEC4E in patient tissues and cancer cell lines. In patient samples, CLEC4E shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC4E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
